Bayer Counters Gen-Probe Arbitration Claims, Alleges NAT Development Delay
This article was originally published in The Gray Sheet
Executive Summary
Gen-Probe is assuring investors that commercial launch of its Tigris molecular diagnostic/nucleic acid testing instrument is forthcoming
You may also be interested in...
Gen-Probe Relying On Tigris To Boost Overseas Blood Screen Market Share
Gen-Probe projects a U.S. market launch in the first half of 2004 for its Tigris DTS fully automated, high-throughput molecular diagnostic instrument system
Bayer Diagnostics/Gen-Probe Primed For HCV Assay Panel Review, Arbitration
Gen-Probe is entering arbitration with hepatitis C assay development partner Bayer Diagnostics while simultaneously preparing for FDA panel review of the quantitative test Dec. 13
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.